Departments and specialties

Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota. Staff skilled in dozens of specialties work together to ensure quality care and successful recovery.


Researchers at Mayo Clinic are studying new ways to diagnose and treat cholangiocarcinoma. This research is conducted as part of the Gastrointestinal Cancer Program and in coordination with Mayo Clinic Comprehensive Cancer Center.

Mayo Clinic Comprehensive Cancer Center receives funding from the National Cancer Institute (NCI) and is an NCI-designated comprehensive cancer center — recognition for an institution's scientific excellence and multidisciplinary resources focused on cancer prevention, diagnosis and treatment.

Areas of research include:

  • Studying the association of aspirin and statin medications with a reduced risk of cholangiocarcinoma
  • Investigating the molecular genetics of a tumor and identifying biomarkers, which may aid in early diagnosis or lead to new targeted therapies
  • Doing clinical trials for new targeted therapies, which is possible because of Mayo Clinic's high patient volume for primary sclerosing cholangitis and bile duct cancer
  • Improving safety of procedures and developing new ones
  • Proving that the biomarker CA 19-9 is useful for staging cholangiocarcinoma and understanding the prognosis for people with the disease


See a list of publications about cholangiocarcinoma by Mayo Clinic doctors on PubMed, a service of the National Library of Medicine.